-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Protalix BioTherapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q2 2024.
- Protalix BioTherapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$69K, a 122% decline year-over-year.
- Protalix BioTherapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was -$456K.
- Protalix BioTherapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $254K, a 52.1% decline from 2022.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)